These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27432932)

  • 41. Emerging targeted therapies for breast cancer.
    Arnedos M; Seidman AD
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):321-40. PubMed ID: 17512452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy.
    Abouharb S; Moulder S
    Curr Oncol Rep; 2015 Mar; 17(3):431. PubMed ID: 25691085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Avastin saga reveals debate over clinical trial endpoints.
    Sharma SP
    J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
    [No Abstract]   [Full Text] [Related]  

  • 44. Trial data lacking for elderly patients with breast cancer.
    Nelson NJ
    J Natl Cancer Inst; 2000 Dec; 92(24):1968-9. PubMed ID: 11121451
    [No Abstract]   [Full Text] [Related]  

  • 45. Checkpoint inhibitors in breast cancer: hype or promise?
    McArthur HL
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
    [No Abstract]   [Full Text] [Related]  

  • 46. Role of Herceptin in primary breast cancer: views from North America and Europe.
    Leyland-Jones B; Smith I
    Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
    Abair T; O'Shaughnessy J
    Clin Breast Cancer; 2011 Feb; 11(1):15-9. PubMed ID: 21989832
    [No Abstract]   [Full Text] [Related]  

  • 48. Adjuvant chemotherapy in the elderly.
    Biganzoli L; Aapro M
    Ann Oncol; 2003; 14 Suppl 3():iii1-3. PubMed ID: 12821531
    [No Abstract]   [Full Text] [Related]  

  • 49. Targeted Therapies for Brain Metastases from Breast Cancer.
    Venur VA; Leone JP
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Developments in Breast Cancer 2017-2018: New Drugs, New Drug Classes-and the Prospect of More to Come.
    Kaklamani VG
    Oncology (Williston Park); 2017 Dec; 31(12 Suppl 1):6-7. PubMed ID: 29299885
    [No Abstract]   [Full Text] [Related]  

  • 51. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.
    Adunlin G; Cyrus JW; Dranitsaris G
    Breast Cancer Res Treat; 2015 Dec; 154(3):591-608. PubMed ID: 26596731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant therapies for very young women with early stage breast cancer.
    Freedman RA; Partridge AH
    Breast; 2011 Oct; 20 Suppl 3():S146-9. PubMed ID: 22015283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 54. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
    Chandarlapaty S; Modi S
    J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
    [No Abstract]   [Full Text] [Related]  

  • 55. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
    Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.
    von Minckwitz G; Martin M; Wilson G; Alba E; Schmidt M; Biganzoli L; Awada A
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):315-31. PubMed ID: 23116625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Next-generation targeted agents in HER2-positive metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
    [No Abstract]   [Full Text] [Related]  

  • 58. Advances in the treatment of breast cancer.
    Moulder S; Hortobagyi GN
    Clin Pharmacol Ther; 2008 Jan; 83(1):26-36. PubMed ID: 18091763
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [BOLERO -- another remarkable step in treatment of breast cancer].
    Rubovszky G; Láng I
    Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant systemic therapy for older adults with early-stage breast cancer.
    Pal SK; Mortimer J
    Womens Health (Lond); 2009 May; 5(3):251-62. PubMed ID: 19392611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.